The Latest Research on CDK 4/6 Inhibitors
Learn about new CDK 4/6 inhibitor research in different breast cancer subtypes, including HER2+ and triple-negative MBC.
Why Knowing Your HER2 Status is Important
Did you know your HER2 status may change over time? Knowing your HER2 status is important to select the best MBC treatment. Learn more here.
Bispecific Antibodies: An Emerging Class Of MBC Drugs
Learn about bispecific antibodies, which bind to two targets instead of one, for MBC treatment.
Metastatic Breast Cancer News from 2021 ESMO
Click here for MBC-related research and reports from ESMO 2021.
Metastatic Breast Cancer News from ASCO 2021
Click here for MBC-related research and reports from ASCO 2021.
St. Gallen International Breast Cancer Conference 2021
Learn about the current research on HR-positive, HER2-Positive, Triple-Negative MBC, and other MBC subtypes from the 2021 St. Gallen International Breast Cancer Conference.